Last reviewed · How we verify

EE20/DRSP (YAZ, BAY86-5300) — Competitive Intelligence Brief

EE20/DRSP (YAZ, BAY86-5300) (EE20/DRSP (YAZ, BAY86-5300)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral contraceptive (combined estrogen-progestin). Area: Contraception / Gynecology.

marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor, progesterone receptor, mineralocorticoid receptor Contraception / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

EE20/DRSP (YAZ, BAY86-5300) (EE20/DRSP (YAZ, BAY86-5300)) — Bayer. EE20/DRSP is an oral contraceptive combining ethinyl estradiol and drospirenone to prevent ovulation and thicken cervical mucus.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EE20/DRSP (YAZ, BAY86-5300) TARGET EE20/DRSP (YAZ, BAY86-5300) Bayer marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor, progesterone receptor, mineralocorticoid receptor
OC - Drospirenone plus Ethynylestradiol OC - Drospirenone plus Ethynylestradiol Federico II University marketed Combined oral contraceptive Estrogen receptor, progesterone receptor, mineralocorticoid receptor
YAZ® YAZ® Teva Pharmaceuticals USA marketed Oral contraceptive (combined estrogen-progestin) Progesterone receptor, estrogen receptor, mineralocorticoid receptor
Ethinyl Estradiol / Norgestimate Oral Tablet Ethinyl Estradiol / Norgestimate Oral Tablet University of Colorado, Denver marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptor and progesterone receptor
All participants (Aviane) All participants (Aviane) Oregon Health and Science University marketed Oral contraceptive (combined estrogen-progestin) Progesterone receptor, estrogen receptor
low-dose estradiol/noresterone low-dose estradiol/noresterone Organon and Co marketed Oral contraceptive (combined estrogen-progestin) Estrogen receptors (ER-α, ER-β) and progesterone receptors (PR)
FEMCON® Fe FEMCON® Fe Teva Pharmaceuticals USA marketed Oral contraceptive (combined estrogen-progestin) Estrogen and progesterone receptors; LH/FSH suppression

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral contraceptive (combined estrogen-progestin) class)

  1. Bayer · 3 drugs in this class
  2. Organon and Co · 2 drugs in this class
  3. Teva Pharmaceuticals USA · 2 drugs in this class
  4. University of Colorado, Denver · 1 drug in this class
  5. Oregon Health and Science University · 1 drug in this class
  6. Helsinki University Central Hospital · 1 drug in this class
  7. Ironwood Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EE20/DRSP (YAZ, BAY86-5300) — Competitive Intelligence Brief. https://druglandscape.com/ci/ee20-drsp-yaz-bay86-5300. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: